SILO: Silo Pharma Company Short-Term Debt

Silo Pharma, Inc. (SILO) is currently launching mid-stage testing of molecules to combat dementia and depression, as reflected in the financial price action on GURU.Markets, where the indicator stands at 0.00. The business relies on selling licenses to major players, leveraging its patent position in the psychedelics sector. Revenue is generated through innovative nasal drug delivery systems for individuals with PTSD and chronic pain.

This indicator captures total liabilities with a maturity of up to one year, where a reduction in the burden signals a balance sheet recovery but may indicate a temporary halt in expansion. When analyzing short-term debt statistics for a portfolio stress test, it is critical for the investor to weigh liquidity against the costs incurred by Silo Pharma (SILO) for expensive clinical trials of psilocybin-based drugs for Alzheimer's disease.